In short, this paper calls for "Do more math on the front-end of the pipeline."

The core issue is that CEOs of biopharmas aren't compensated as such, so if you were to go to one with mathematical techniques that would take 3 to 6 months to run, (Combining research, bioinformatics, and diff EQ) they would look at you like you're crazy because the timeline and their incentivization is skewed toward not failing a trial.

Trials exceed CEO lifetime, and that's one core issue as to why pharma development isn't done this way today.